[Skip to Content]
[Skip to Content Landing]
Views 1,233
Citations 0
From The Medical Letter on Drugs and Therapeutics
July NaN, 2014

Dolutegravir (Tivicay) for HIV

JAMA. 2014;312(4):428-429. doi:10.1001/jama.2014.8406

The FDA has approved dolutegravir (doll-you-TEG-rah-veer; Tivicay – Viiv Healthcare), an integrase strand transfer inhibitor (INSTI), for treatment of HIV-1 infection in adults and in children ≥12 years old who weigh at least 40 kg. It is the third INSTI to be approved by the FDA; raltegravir and elvitegravir were approved earlier (Table 1).1,2

First Page Preview View Large
First page PDF preview
First page PDF preview